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Safety and Efficacy of Ceftaroline Fosamil in the Management of CommunityAcquired Bacterial Pneumonia
Heather F. DeBellis and Kimberly L. Tackett
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Abstract: Ceftaroline fosamil is a new fifth-generation cephalosporin indicated for the treatment of community-acquired bacterial pneumonia
(CABP). It possesses antimicrobial effects against both Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus
(MRSA), but not against anaerobes. Organisms covered by this novel agent that are commonly associated with CABP are Streptococcus pneumoniae,
Staphylococcus aureus, Haemophilus influenzae, Moraxella catarrhalis, and Klebsiella pneumoniae; however, ceftaroline fosamil lacks antimicrobial activity
against Pseudomonas and Acinetobacter species. FOCUS 1 and FOCUS 2 clinical trials evaluated the use of ceftaroline fosamil in the treatment of CABP
as compared to ceftriaxone. These non-inferiority trials provided evidence that ceftaroline fosamil is as effective and safe as ceftriaxone in the treatment
of CABP. As its role in the treatment has not been well established, ceftaroline fosamil should be reserved for patients at high risk for multidrug-resistant
organisms (MDROs). This review summarizes ceftaroline fosamil’s pharmacokinetic and pharmacodynamic profile, clinical efficacy and safety, and place
in therapy for the treatment and management of CABP.
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Introduction

Pneumonia cases in 2006 collectively contributed to 1.2 million
hospitalizations, which eventually led to over 55,000 patient
deaths in the same year from the disease. When combined
with influenza, pneumonia is the eighth leading cause of death
in the US. Approximately 5.6 million US patients are infected
with community-acquired bacterial pneumonia (CABP)
annually, contributing to costs exceeding $12 billion yearly.1
CABP is defined as an alveolar infection that develops in
the outpatient setting or within 48 hours of hospital admission and is primarily caused by Streptococcus pneumoniae; however, other culprits include Haemophilus influenzae, Moraxella
catarrhalis, Mycoplasma pneumoniae, and Chlamydophila
pneumoniae.1 In contrast, healthcare-associated pneumonia
(HCAP) cases are mainly infected by Legionella pneumophila, Staphylococcus aureus, or other bacteria.2 The specific

pathogenic organisms vary by patient populations and may
be influenced by the disease states of the patient. This can
be additionally challenging for practitioners to identify and
appropriately treat since certain risk factors and comorbidities (eg, alcoholism, COPD, smoking, aspiration, and HIV
infection) can make patients more susceptible to uncommon
causative organisms.2
Physician adherence to the Infectious Diseases Society
of America/American Thoracic Society (IDSA/ATS) treatment guidelines for CABP is paramount because it improves
patient outcomes. According to the current IDSA/ATS
treatment guidelines for CABP, there are different empiric
treatment options for CABP in the outpatient setting. Nonhospitalized patients who are otherwise healthy should receive
monotherapy with a macrolide or doxycycline. In those with
comorbid conditions such as the presence of chronic disease,
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recent antimicrobial use, or risk factors for drug-resistant
S. pneumoniae, a respiratory fluoroquinolone (levofloxacin,
moxifloxacin, or gemifloxacin) or a β-lactam plus a macrolide
is recommended. If a patient is admitted to the hospital, a
respiratory fluoroquinolone or a macrolide plus a β-lactam is
suggested. Additional antibiotic selection can be tailored to
the suspected bacteria, patient risk factors, and environmental
risk factors (eg, admission to the intensive care unit). Practitioners should encourage smoking cessation and promote
pneumococcal and influenza vaccinations in order to aid in
the prevention of CABP.2,3
In the last several years, owing to concerns regarding
multidrug-resistant organisms (MDROs), a new antibiotic
has been developed and approved for use in the treatment
of CABP. Ceftaroline fosamil (Teflaro®) was approved by
the US Food and Drug Administration (FDA) in October
2010. Ceftaroline fosamil is a new extended-spectrum
cephalosporin, β-lactam antibiotics, with activity against
methicillin-resistant Staphylococcus aureus (MRSA) and
penicillin-resistant Streptococcus pneumoniae. 3–5 It also has
Gram-negative coverage against Escherichia coli, Proteus
mirabilis, H. influenzae, M. catarrhalis, Neisseria meningitidis,
as well as wild-type Enterobacteriaceae, but has no activity
against anaerobes. This review summarizes ceftaroline
fosamil’s pharmacokinetic and pharmacodynamic profile, clinical efficacy and safety, and place in therapy for the
treatment and management of CABP.

with the minimum inhibitory concentration (MIC) ranges
are listed in Table 1.12 Ceftaroline has a bacterial spectrum
of activity against organisms that are commonly associated
with CABP including S. pneumoniae, S. aureus, H. influenzae,
M. catarrhalis, and Klebsiella pneumoniae, but does not possess activity against atypical pathogens.12 Resistance to CABP
pathogens has been an increasing concern, promoting the
need for the development of newer antibiotics for the treatment of CABP. A 12-year analysis of pneumococcal resistance
rates has shown an increase in resistance to commonly used
β-lactam agents.4,10,11,13
The Gram-positive anaerobic activity of ceftaroline is
similar to that seen with amoxicillin-clavulanate.9 It has limited activity against the Bacteroides fragilis group, but does have
coverage against β-lactamase negative strains. In addition to
activity against MRSA, ceftaroline exhibits in vitro activity
against vancomycin-intermediate and vancomycin-resistant
S. aureus.8 Ceftaroline has limited activity against Enterococcus
faecalis, Enterococcus faecium, and Corynebacterium jeikeium.
Ceftaroline is still susceptible to extended spectrum
β-lactamases, cephalosporinases, and carbapenemases.14 There
are current ongoing studies on the drug in combination with
the β-lactamase inhibitor, avibactam, in order to expand its
antimicrobial coverage.4,14 The addition of avibactam restores
ceftaroline’s activity against Enterobacteriaceae strains that
are resistant to other broad spectrum β-lactam antibiotics.

Mechanism of Action

Following intravenous (IV) administration, the conversion of
the prodrug ceftaroline fosamil to active form ceftaroline is
dependent upon metabolism by phosphatase enzymes in the
plasma.5–7 A small portion of the active drug then undergoes metabolism via hydrolysis to the β-lactam ring to form
an inactive metabolite, ceftaroline-M-1.9 Ceftaroline and its
metabolites are primarily eliminated by the kidneys with a
renal clearance of 95.6 and 86.7 mL/minute for single and
multiple doses, respectively.5,9,15 Approximately 88% of the
drug was found in the urine and 6% in the feces 48 hours following the administration of a 600 mg dose,.5,8 In vitro studies indicate that ceftaroline is not metabolized by cytochrome
P-450 isoenzymes, resulting in less drug interactions and no
dosing adjustments for impaired hepatic function.4

Ceftaroline fosamil is classified as a fifth-generation cephalosporin. It is a prodrug that was developed by modifying the
structure of a fourth-generation cephalosporin, cefozopran.5–7
The antibacterial activity of ceftaroline occurs through binding to penicillin-binding proteins (PBPs) and interrupting
cell wall synthesis, similar to other β-lactam antibiotics.7–9
It binds to PBPs 1–4 with an especially high affinity for PBP2a,
which is associated with methicillin resistance. An oxine ring
provides ceftaroline with activity against β-lactamase producing microorganisms and a 1,2,4-thiadiazole ring gives it
Gram-negative activity. Ceftaroline provides improved activity against S. aureus and S. pneumoniae as a result of the 3′
side chain mediating improved binding to PBPs that exhibit
decreasing binding affinity for standard β-lactams.10

Antimicrobial Activity

Ceftaroline exhibits both bactericidal and time-dependent
killing activity.4 Antimicrobial effects are a result of binding
and irreversible inactivation of essential PBPs, leading to the
inhibition of bacterial cell-wall biosynthesis, lysis, and death.
It has a broad spectrum of activity including both Grampositive and Gram-negative bacteria as well as MRSA.8 The
spectrum of activity against Gram-negative bacilli is similar
to that seen with ceftriaxone.11 Susceptible bacterial isolates
from patients enrolled in the FOCUS 1 and 2 studies along
2
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Pharmacokinetics

Table 1. Antimicrobial spectrum of activity.12,18–21
Organism

MIC range (mg/L)

S. pneumoniae

#0.015–0.12

S. pneumoniae (multidrug resistant)

#0.015–0.12

S. aureus

0.12–0.5

H. influenzae

#0.015–0.5

Haemophilus parainfluenzae

#0.015–1

E. coli

0.03–.16

K. pneumoniae

0.06–0.5

Ceftaroline fosamil in CABP

Single and multiple dose studies show that ceftaroline
displays linear pharmacokinetics with proportional increases
in the maximum concentration (Cmax) and area under the
plasma drug concentration-time curve (AUC) with increases
in dose.8,14,15 In a double-blind, placebo-controlled multipleascending dose study, the AUC and Cmax of ceftaroline
increased proportionately with dose following the IV administration of 300 or 600 mg every 12 hours or 800 mg every
24 hours for multiple days.16,17 There has been shown to be no
ceftaroline accumulation following the administration of multiple doses at either 12 or 24 hours for up to 14 days.7 Plasma
protein binding is approximately 20% and decreases with
increasing concentrations.6,7,9 The median steady-state volume
of distribution following a single 600 mg dose is 20.3 L with
a range of 18.3–21.6 L, which is similar to extracellular fluid
volume, indicating distribution into total body fluids. Body
weight is a predictor of volume of distribution while creatinine
clearance (CrCl) can be used to predict drug elimination.8
The elimination half-life of ceftaroline is estimated to be
2.6 hours in patients with normal renal function; the halflife of the inactive metabolite is 4.5 hours.5–7,9 The AUC and
half-life increase by an estimated 25 and 14%, respectively,
in patients with mild renal impairment (estimated CrCl
50–80 mL/minute), and the AUC increases by up to 50% in
patients with moderate to severe renal impairment (estimated
CrCl 30–50 mL/minute).5,6 Therefore, dosage adjustment
is recommended in patients with moderate to severe renal
impairment and with end-stage renal disease (ESRD) receiving hemodialysis (estimated CrCl 15–50 mL/minute). The
manufacturer recommends that ceftaroline doses be scheduled
for administration following dialysis as the drug is removed
during hemodialysis.5 In vitro studies indicate that ceftaroline
is not metabolized by cytochrome P-450 isoenzymes, resulting in less drug interactions and no adjustments for impaired
hepatic function.4
Elderly patients may require a dosage adjustment for ceftaroline fosamil because of age-related changes in renal function.5 The mean AUC and half-life were shown to be increased
by 33 and 41%, respectively, in healthy elderly patients ($65
years of age) compared to healthy young adults (18–45 years of
age) following a single 600 mg dose.5
There is limited data establishing the safety and efficacy
of ceftaroline fosamil in pediatric patients (,18 years of age).5
The pharmacokinetics of ceftaroline are similar in adolescents to those observed in healthy adult patients. In patients
of 12–17 years of age with normal renal function, the mean
plasma clearance and volume of distribution following an
8 mg/kg dose were similar to those observed in healthy adult
subjects after receiving a 600 mg dose. However, Cmax and
AUC were reduced by 10 and 23%, respectively.5

Pharmacodynamics

Ceftaroline exhibits bactericidal, time-dependent, and
concentration-independent killing.6,8 The primary predictor of

bacteriologic and clinical efficacy is the percentage of time that
the free drug remains above the MIC for the pathogen.8 The
time the free drug remains above the MIC for staphylococci
is 30% of the total administration time for ceftaroline to be
bacteriostatic and 40% for S. pneumoniae and Gram-negative
bacilli.4,8,9 Ceftaroline demonstrates bactericidal activity when
the time the free drug remains above the MIC reaches 50%
in staphylococci and 60% in Gram-negative bacilli. Neither
protein binding nor methicillin and penicillin resistance have
been shown to affect this parameter. Ceftaroline demonstrates
a limited post-antibiotic effect against most pathogens except
S. aureus, against which it has been shown to possess a longer
effect.

Clinical Efficacy

The FOCUS 1 and FOCUS 2 clinical trials are randomized,
double-blind, and multicenter phase III studies evaluating the
safety and efficacy of ceftaroline fosamil when compared to
ceftriaxone for the treatment of patients with CABP. Results
of the FOCUS 1 and 2 studies are summarized in Tables 2
and 3. Study participants were randomized (1:1) to receive
drug therapy for 5–7 days of either ceftaroline fosamil 600 mg
every 12 hours or ceftriaxone 1 g every 24 hours if they were
hospitalized with CABP, requiring IV therapy, and having a
pneumonia outcomes research team (PORT) risk class score
of III or IV. The FOCUS 1 and FOCUS 2 clinical trials were
intended as parallel, methodologically similar (with the exclusion of two doses of clarithromycin given on day 1 during
FOCUS 1 only) comparative analyses, which did not permit
change to oral medications for drug therapy completion. 3,18,19
The primary endpoint of the FOCUS program was to
determine the non-inferiority of ceftaroline fosamil in clinical
cure rates when compared with ceftriaxone in the clinically
evaluable (CE) and modified intent-to-treat efficacy (MITTE)
populations at the test-of-cure (TOC) visit. A clinical cure
was defined as an afebrile condition for 24 consecutive hours
and conclusion of signs and symptoms of CABP or determination that antibiotic therapy was no longer necessary, and a
relapse was defined as the return of symptoms requiring antibiotics during the late follow-up (LFU) visit.3,20 The TOC
visit occurred 8–15 days from the last dose of study medication administered, and then the LFU occurred 21–35 days
from the last dose of study medication.3,20
Table 2. Clinical cure rates in CE patients.
Ceftaroline
group

Ceftriaxone
group

Difference,
(95% confidence
interval [CI])

FOCUS 1

86.6%

78.2%

8.4%, (1.4–15.4%)

FOCUS 2

82.1%

77.2%

4.9%, (−2.5–12.5%)

Integrated 84.3%
efficacy
analysis

77.7%

6.7%, (1.6–11.8%)
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The FOCUS 1 clinical cure rates in CE patients were
86.6% in the ceftaroline fosamil group versus 78.2% in the
ceftriaxone group (difference, 8.4%; 95% confidence interval
[CI], 1.4–15.4%). During FOCUS 2, the clinical cure rates
in the CE population were 82.1% in the ceftaroline fosamil
group versus 77.2% in the ceftriaxone group (difference, 4.9%;
95% CI, −2.5–12.5%). In the integrated efficacy analysis of
the two trials, the clinical cure rates in the CE population
were 84.3% in the ceftaroline fosamil group versus 77.7% in
the ceftriaxone group (difference, 6.7%; 95% CI, 1.6–11.8%).
Hence, non-inferiority was established for ceftaroline fosamil
when compared to ceftriaxone. Refer to Table 2.3,9,18,19
The FOCUS 1 clinical cure rates in MITTE patients
were 83.8% in the ceftaroline fosamil group versus 77.7% in
the ceftriaxone group (difference, 6.2%; 95% confidence interval [CI], −0.2–12.6%). During FOCUS 2, the clinical cure
rates in the MITTE population were 81.3% in the ceftaroline
fosamil group versus 75.5% in the ceftriaxone group (difference, 5.9%; 95% CI, −1.0–12.7%). The integrated summary
reports clinical cure rates in MITTE patients as 82.6 versus
76.6% for ceftaroline fosamil and ceftriaxone, respectively
(difference, 6.0%; 95% CI, 1.4–10.7%), proving ceftaroline
fosamil to be non-inferior to therapy with ceftriaxone. Refer
to Table 3.3,9,18,19
Clinical cure rates for the study medication, ceftaroline
fosamil, were found to be non-inferior to those of ceftriaxone
across all predefined study groups during the entire FOCUS
program. Furthermore, clinical relapse rates at the time of
LFU were similar between the two study populations for the
CE and MITTE groups as described in the integrated analysis.
Therefore, comparable efficacy of ceftaroline fosamil 600 mg
administered intravenously every 12 hours was established to
ceftriaxone 1 g administered intravenously every 24 hours in
hospitalized patients with CABP requiring IV therapy and
having a PORT risk class score of III or IV.3,9,18,19

Tolerability and Safety

Over the course of the FOCUS 1 and FOCUS 2 phase III
clinical trials, all enrolled patients (1228 total patients) were
followed for treatment-emergent adverse events (TEAEs). Sixhundred and thirteen patients were monitored from the first
IV administration of ceftaroline fosamil until the TOC visit,
and 615 patients were equally monitored in the ceftriaxone
Table 3. Clinical cure rates in MITTE patients.
Ceftaroline
group

Ceftriaxone Difference,
group
(95% confidence
interval [CI])

FOCUS 1

83.8%

77.7%

6.2%, (−0.2–12.6%)

FOCUS 2

81.3%

75.5%

5.9%, (−1.0–12.7%)

Integrated 82.6%
efficacy
analysis

76.6%

6.0%, (1.4–10.7%)
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group. Patients who were administered any amount of study
medication were included in the safety analysis. Also, serious
adverse events (SAEs) including deaths that transpired within
30 days of the last study medication dose received and/or up to
the LFU visit were reported. Study medication mean exposure
was 6.5 ± 1.1 days for both study populations. Patients participated in scheduled laboratory visits from initiation until the
TOC visit, while unscheduled laboratory visits were utilized
until the LFU visit.3,18,19,21
The following safety results are documented from the
integrated summary report of the FOCUS 1 and FOCUS 2
clinical studies. The most often reported TEAEs in the ceftaroline fosamil treatment population were diarrhea (4.2%),
headache (3.4%), and insomnia (3.1%). Approximately 75% of
patients noticed only mild TEAEs or no TEAEs in either
treatment population; therefore, the severity-based distribution of TEAEs was consistent between the two treatment
populations. The overall incidence rates of adverse events
(AEs) were comparable between the ceftaroline fosamil and
ceftriaxone populations, respectively: patients experiencing at
least one TEAE (47.0 vs. 45.7%), SAE (11.3 vs. 11.7%), discontinuation because of an AE (4.4 vs. 4.1%), or death (2.4 vs.
2.0%).3,21
Twenty-seven total deaths occurred throughout the
FOCUS studies; 15 in the ceftaroline fosamil population and
12 in the ceftriaxone population. Of the deaths recorded, the
investigator classified them by type or organ system. Two deaths
(one from each population) could have been linked to study
medication when appraised by the investigator. Deaths associated with cardiac disorders (2 vs. 7), infections and infestations
(3 vs. 1), neoplasms (4 vs. 0), respiratory disorders (4 vs. 3),
and general disorders such as sudden death and multiple organ
disorder (2 vs. 1) occurred in the ceftaroline fosamil and ceftriaxone treatment arms, respectively.3,21
Seven SAEs were recorded in more than two patients
from the ceftaroline fosamil group, which included pneumonia (as defined by worsening or relapse of CABP or nosocomial pneumonia, nine patients), pleural effusion (five patients),
pulmonary embolism (five patients), chronic obstructive pulmonary disease (four patients), pyothorax (four patients),
respiratory failure (four patients), and malignant lung neoplasm (three patients). The investigator assessed the SAEs,
and the majority (95.7% in the ceftaroline fosamil population
and 91.7% in the ceftriaxone population) were disregarded
as not related to the study medication. Therefore, no safety
concerns were expressed. No occurrence of TEAE was documented in more than two subjects in the ceftaroline fosamil
population, leading to the discontinuation of the study medication or withdrawal from the clinical trial. However, pneumonia (as defined above), pulmonary embolism, respiratory
failure, septic shock, and sudden death each occurred in two
patients in the ceftaroline fosamil population, which led to
the discontinuation of the study medication or withdrawal
from the clinical trial for these reported cases. Ten patients

Ceftaroline fosamil in CABP

in the ceftaroline fosamil population and nine patients from
the ceftriaxone population either stopped the study medication or withdrew from the study. The aforementioned SAEs
and TEAEs leading to the discontinuation of the study medication revealed an inadequate therapeutic response, which
caused prolonged hospitalizations (meets criteria of the SAE
definition) or represented AEs that resulted in death (withdrawal from the study).3,21
In general, ceftaroline fosamil was found to be safe and
well tolerated overall. The use of ceftaroline fosamil did not
possess any unexpected safety considerations. Ceftaroline fosamil is classified as pregnancy category B. There are no wellcontrolled studies on pregnant women, and it is unknown if
ceftaroline is excreted in breast milk.5 Therefore, it is recommended by the manufacturer that ceftaroline fosamil only be
prescribed if the potential benefit justifies the potential risk to
the fetus.
Prescribers should exercise caution in patients with past
allergic skin reactions to any other β-lactam antibiotics and
ceftaroline fosamil should be immediately stopped if a reaction
develops. Ceftaroline fosamil has a similar safety and tole
rability profile as observed with ceftriaxone and other agents
of the cephalosporin class.3,5,21

Dosage and Administration

Ceftaroline fosamil is available in 600 and 400 mg reconstitutable vials of powder for injection.5 The recommended dose in
adults (greater than or equal 18 years of age) with normal renal
function (CrCl greater than 50 mL/minute) is 600 mg every
12 hours by IV infusion administered over one hour. Recommended duration of therapy for CABP is 5–7 days based on
the severity of the infection and response to therapy.
Dosing adjustment of ceftaroline fosamil is required
in patients with impaired renal function and patients with
ESRD on intermittent hemodialysis.5,7,15 Patients with mild
to moderate renal impairment have an increased AUC of 19
and 52%, respectively, with an increased half-life of 27 and
58%, respectively, after the infusion of a single 600 mg dose.
The Cmax was unaltered in patients with mild or moderate
renal impairment, but was slightly higher in subjects with
severe renal impairment as compared to patients with normal
renal function. Therefore, it is recommended that the dosage
be adjusted to 400 mg every 12 hours in patients whose CrCl
is greater than 30 but less than or equal to 50 mL/minute, and
further decreased to 300 mg every 12 hours in patients whose
CrCl is greater than or equal to 15 mL/minute but less than or
equal to 30 mL/minute, and then decreased to 200 mg every
12 hours in patients whose CrCl is less than 15 mL/minute
with ESRD, including patients receiving hemodialysis.5,8,15
Patients receiving intermittent hemodialysis, after receiving a single 400 mg dose of ceftaroline fosamil, had a 167%
higher mean AUC as compared to patients with normal renal
function.7,8 Additionally, the Cmax was 74% higher and the
half-life was approximately 123% longer. Following a four

hour hemodialysis session, 21.6% (76 mg) of ceftaroline was
measured in the dialysate. Therefore, ceftaroline fosamil should
be administered following hemodialysis on dialysis days.5,7,15

Place in Therapy

The FOCUS trials established that ceftaroline fosamil was
non-inferior to ceftriaxone in the treatment of non-ICU
patients with CABP; however, it has not been established
as preferred use even though the integrated analysis by File
et al. found that ceftaroline demonstrated superiority in
most of the FOCUS study groups and subgroups.18–20 The
Average Wholesale Price of one vial of ceftaroline fosamil
is $41, which corresponds to about $80 per day for therapy,
and the total cost of treatment is higher as compared to other
common treatments such as IV cephalosporins and respiratory fluoroquinolones; additionally, no cost-benefit studies
of ceftaroline fosamil in the treatment of CABP have been
conducted.
Ceftaroline fosamil does represent a new treatment option
for the indication of CABP in the setting of patients at risk for
MDROs. Antimicrobial resistance, an aging population, and
concomitant comorbidities in the community have changed
prescribing practices for CABP. Initial therapy in the inpatient
setting may consist of combination therapy and antimicrobial
coverage of resistant pathogens.6 Utilization of local antibiograms and knowledge of resistance patterns in the community
will help to guide selection of antimicrobial agents. Ceftaroline
provides antimicrobial activity against wild-type and mutant
pathogens responsible for CABP, exhibiting lower MICs for
S. aureus and S. pneumoniae as compared to ceftriaxone and
other cephalosporins. Advantages of ceftaroline include its
dosing, minimal drug interaction profile, and low resistance
to common CABP pathogens, making it an alternative for
patients unable to tolerate or respond to other antimicrobial
therapies. Patients identified as MRSA colonized or having
experienced past episodes of drug-resistant S. pneumoniae may
benefit from treatment with ceftaroline fosamil initially for
CABP, though there are no current clinical data to support its
use in this population.3,7

Conclusion

Ceftaroline fosamil represents a new treatment option for
patients with CABP, possessing antimicrobial activity against
both Gram-positive and Gram-negative bacteria. Antimicrobial treatment for CABP has changed over the years as a
result of antibiotic resistance, an aging population, and patient
comorbidities.6 Ceftaroline fosamil has been labeled as the
first new antibiotic in the IDSA initiative to develop ten new
antibiotics by the year 2020.22 Practitioners should reserve
this antibiotic for patients with risk factors for pathogens with
resistance to other antimicrobials that are more cost effective.
It does have a spectrum of activity that covers typical pathogens in CABP, but its role in treatment should be reserved for
those patients with a high risk of MDROs.
Clinical Medicine Reviews in Therapeutics 2014:6
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